Accurately identifying patients who are excellent candidates or unsuitable for a medication: A novel approach

Charles South, Ajohn Rush, Thomas J. Carmody, Manish K. Jha, Madhukar H. Trivedi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: The objective of the study was to determine whether a unique analytic approach – as a proof of concept – could identify individual depressed outpatients (using 30 baseline clinical and demographic variables) who are very likely (75% certain) to not benefit (NB) or to remit (R), accepting that without sufficient certainty, no prediction (NP) would be made. Methods: Patients from the Combining Medications to Enhance Depression Outcomes trial treated with escitalopram (S-CIT) + placebo (n=212) or S-CIT + bupropion-SR (n=206) were analyzed separately to assess replicability. For each treatment, the elastic net was used to identify subsets of predictive baseline measures for R and NB, separately. Two different equations that estimate the likelihood of remission and no benefit were developed for each patient. The ratio of these two numbers characterized likely outcomes for each patient. Results: The two treatment cells had comparable rates of remission (40%) and no benefit (22%). In S-CIT + bupropion-SR, 11 were predicted NB of which 82% were correct; 26 were predicted R – 85% correct (169 had NP). For S-CIT + placebo, 13 were predicted NB – 69% correct; 44 were predicted R – 75% correct (155 were NP). Overall, 94/418 (22%) patients were identified with a meaningful degree of certainty (69%–85% correct). Different variable sets with some overlap were predictive of remission and no benefit within and across treatments, despite comparable outcomes. Conclusion: In two separate analyses with two different treatments, this analytic approach – which is also applicable to pretreatment laboratory tests – identified a meaningful proportion (over 20%) of depressed patients for whom a treatment outcome was predicted with sufficient certainty that the clinician can elect to strongly recommend for or choose to avoid a particular treatment. Different persons seem to be remitting or not benefiting with these two different treatments.

Original languageEnglish (US)
Pages (from-to)3001-3010
Number of pages10
JournalNeuropsychiatric Disease and Treatment
Volume13
DOIs
StatePublished - Dec 15 2017

Fingerprint

Bupropion
Therapeutics
Placebos
Citalopram
Outpatients
Demography

Keywords

  • Analytic approach
  • Depression
  • Elastic net
  • Patient selection
  • Treatment response

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Accurately identifying patients who are excellent candidates or unsuitable for a medication : A novel approach. / South, Charles; Rush, Ajohn; Carmody, Thomas J.; Jha, Manish K.; Trivedi, Madhukar H.

In: Neuropsychiatric Disease and Treatment, Vol. 13, 15.12.2017, p. 3001-3010.

Research output: Contribution to journalArticle

@article{6024d1d6bdec449abf51c4c314a8e1b2,
title = "Accurately identifying patients who are excellent candidates or unsuitable for a medication: A novel approach",
abstract = "Objective: The objective of the study was to determine whether a unique analytic approach – as a proof of concept – could identify individual depressed outpatients (using 30 baseline clinical and demographic variables) who are very likely (75{\%} certain) to not benefit (NB) or to remit (R), accepting that without sufficient certainty, no prediction (NP) would be made. Methods: Patients from the Combining Medications to Enhance Depression Outcomes trial treated with escitalopram (S-CIT) + placebo (n=212) or S-CIT + bupropion-SR (n=206) were analyzed separately to assess replicability. For each treatment, the elastic net was used to identify subsets of predictive baseline measures for R and NB, separately. Two different equations that estimate the likelihood of remission and no benefit were developed for each patient. The ratio of these two numbers characterized likely outcomes for each patient. Results: The two treatment cells had comparable rates of remission (40{\%}) and no benefit (22{\%}). In S-CIT + bupropion-SR, 11 were predicted NB of which 82{\%} were correct; 26 were predicted R – 85{\%} correct (169 had NP). For S-CIT + placebo, 13 were predicted NB – 69{\%} correct; 44 were predicted R – 75{\%} correct (155 were NP). Overall, 94/418 (22{\%}) patients were identified with a meaningful degree of certainty (69{\%}–85{\%} correct). Different variable sets with some overlap were predictive of remission and no benefit within and across treatments, despite comparable outcomes. Conclusion: In two separate analyses with two different treatments, this analytic approach – which is also applicable to pretreatment laboratory tests – identified a meaningful proportion (over 20{\%}) of depressed patients for whom a treatment outcome was predicted with sufficient certainty that the clinician can elect to strongly recommend for or choose to avoid a particular treatment. Different persons seem to be remitting or not benefiting with these two different treatments.",
keywords = "Analytic approach, Depression, Elastic net, Patient selection, Treatment response",
author = "Charles South and Ajohn Rush and Carmody, {Thomas J.} and Jha, {Manish K.} and Trivedi, {Madhukar H.}",
year = "2017",
month = "12",
day = "15",
doi = "10.2147/NDT.S139577",
language = "English (US)",
volume = "13",
pages = "3001--3010",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Accurately identifying patients who are excellent candidates or unsuitable for a medication

T2 - A novel approach

AU - South, Charles

AU - Rush, Ajohn

AU - Carmody, Thomas J.

AU - Jha, Manish K.

AU - Trivedi, Madhukar H.

PY - 2017/12/15

Y1 - 2017/12/15

N2 - Objective: The objective of the study was to determine whether a unique analytic approach – as a proof of concept – could identify individual depressed outpatients (using 30 baseline clinical and demographic variables) who are very likely (75% certain) to not benefit (NB) or to remit (R), accepting that without sufficient certainty, no prediction (NP) would be made. Methods: Patients from the Combining Medications to Enhance Depression Outcomes trial treated with escitalopram (S-CIT) + placebo (n=212) or S-CIT + bupropion-SR (n=206) were analyzed separately to assess replicability. For each treatment, the elastic net was used to identify subsets of predictive baseline measures for R and NB, separately. Two different equations that estimate the likelihood of remission and no benefit were developed for each patient. The ratio of these two numbers characterized likely outcomes for each patient. Results: The two treatment cells had comparable rates of remission (40%) and no benefit (22%). In S-CIT + bupropion-SR, 11 were predicted NB of which 82% were correct; 26 were predicted R – 85% correct (169 had NP). For S-CIT + placebo, 13 were predicted NB – 69% correct; 44 were predicted R – 75% correct (155 were NP). Overall, 94/418 (22%) patients were identified with a meaningful degree of certainty (69%–85% correct). Different variable sets with some overlap were predictive of remission and no benefit within and across treatments, despite comparable outcomes. Conclusion: In two separate analyses with two different treatments, this analytic approach – which is also applicable to pretreatment laboratory tests – identified a meaningful proportion (over 20%) of depressed patients for whom a treatment outcome was predicted with sufficient certainty that the clinician can elect to strongly recommend for or choose to avoid a particular treatment. Different persons seem to be remitting or not benefiting with these two different treatments.

AB - Objective: The objective of the study was to determine whether a unique analytic approach – as a proof of concept – could identify individual depressed outpatients (using 30 baseline clinical and demographic variables) who are very likely (75% certain) to not benefit (NB) or to remit (R), accepting that without sufficient certainty, no prediction (NP) would be made. Methods: Patients from the Combining Medications to Enhance Depression Outcomes trial treated with escitalopram (S-CIT) + placebo (n=212) or S-CIT + bupropion-SR (n=206) were analyzed separately to assess replicability. For each treatment, the elastic net was used to identify subsets of predictive baseline measures for R and NB, separately. Two different equations that estimate the likelihood of remission and no benefit were developed for each patient. The ratio of these two numbers characterized likely outcomes for each patient. Results: The two treatment cells had comparable rates of remission (40%) and no benefit (22%). In S-CIT + bupropion-SR, 11 were predicted NB of which 82% were correct; 26 were predicted R – 85% correct (169 had NP). For S-CIT + placebo, 13 were predicted NB – 69% correct; 44 were predicted R – 75% correct (155 were NP). Overall, 94/418 (22%) patients were identified with a meaningful degree of certainty (69%–85% correct). Different variable sets with some overlap were predictive of remission and no benefit within and across treatments, despite comparable outcomes. Conclusion: In two separate analyses with two different treatments, this analytic approach – which is also applicable to pretreatment laboratory tests – identified a meaningful proportion (over 20%) of depressed patients for whom a treatment outcome was predicted with sufficient certainty that the clinician can elect to strongly recommend for or choose to avoid a particular treatment. Different persons seem to be remitting or not benefiting with these two different treatments.

KW - Analytic approach

KW - Depression

KW - Elastic net

KW - Patient selection

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=85038869774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038869774&partnerID=8YFLogxK

U2 - 10.2147/NDT.S139577

DO - 10.2147/NDT.S139577

M3 - Article

C2 - 29290685

AN - SCOPUS:85038869774

VL - 13

SP - 3001

EP - 3010

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -